InvestorsObserver
×
News Home

Mind Medicine (MindMed) Inc (MNMD) is lower by -10.71% in a Week, Should You Sell?

Thursday, October 12, 2023 10:00 AM | InvestorsObserver Analysts

Mentioned in this article

Mind Medicine (MindMed) Inc (MNMD) is lower by -10.71% in a Week, Should You Sell?

The 69 rating InvestorsObserver gives to Mind Medicine (MindMed) Inc (MNMD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 93 percent of stocks in the Biotechnology industry, MNMD’s 69 overall rating means the stock scores better than 69 percent of all stocks.

Overall Score - 69
MNMD has an Overall Score of 69. Find out what this means to you and get the rest of the rankings on MNMD!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 69 would rank higher than 69 percent of all stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Mind Medicine (MindMed) Inc Stock Today?

Mind Medicine (MindMed) Inc (MNMD) stock is trading at $2.75 as of 9:53 AM on Thursday, Oct 12, a loss of -$0.12, or -4.18% from the previous closing price of $2.87. The stock has traded between $2.68 and $2.87 so far today. Volume today is below average. So far 81,401 shares have traded compared to average volume of 432,567 shares. Click Here to get the full Stock Report for Mind Medicine (MindMed) Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App